Maria Grazia Roncarolo, MD
Maria Grazia Roncarolo, MD, Co-Founder, President and Head of R&D Tr1X Inc., George D Smith Professor of Stem Cell transplantation and Regenerative medicine, Emerita, Stanford University. Maria Grazia Roncarolo is a pediatric immunologist by training and an expert in cell and gene therapy. She is recognized globally for her leadership in translating scientific discoveries in immune mediated diseases and regenerative medicine into novel patient therapies, including the world’s […]
David de Vries, MPhil
David has over a decade of experience founding and scaling companies at the intersection of healthcare and technology. Prior to Tr1X, David was Co-Founder and COO of Arine, a therapeutic optimization company he helped launch and scale to serve millions of patients across the US. Before that, he worked at Proteus Digital Health, one of […]
Bill Lis
William Lis has 30 years of biopharmaceutical industry experience in executive and board roles. He has been an Independent Director of Zai Laboratories, Inc. (NASDAQ: ZLAB) since 2018. He is also Executive Chairman of Tr1X, after previously serving as Interim CEO from 2023 to 2025. Previously Mr. Lis served as an Independent Director of Eidos, Therapeutics, Inc., developer of Attruby®, from […]
Tao Fu, MBA
Mr. Fu is the Chief Executive Office and co-founder of Attovia Therapeutics, as well as a Venture Partner at Frazier Life Sciences. Mr. Fu is a seasoned industry leader with over 25 years of executive experience in the pharmaceutical and biotech industries, including leadership roles at Zai Lab, Portola Pharmaceuticals, Bristol-Myers Squibb and Johnson & […]
Leon Chen, PhD, MBA
Dr. Chen is a partner at The Column Group, currently serving on the board of directors of Eikon Therapeutics, Remix Therapeutics and Velia, in addition to Tr1X. Previously, he was a Venture Partner at OrbiMed focusing on company creation and investing in early-stage biotech companies. In this capacity he took on interim management roles at […]
Katherine High, MD
Dr. Kathy High is an accomplished hematologist with a longstanding interest in gene therapy for genetic disease. Most recently, Dr. High served as the President, Therapeutics of AskBio, a subsidiary of Bayer AG, and as a member of AskBio’s board of directors. Previously, Dr. High co-founded Spark Therapeutics, Inc. and from September 2014 to December […]